相似文献
1
New Actions on Actionable Mutations in Lung Cancers.
Cancers (Basel). 2023 May 26;15(11):2917. doi: 10.3390/cancers15112917.
2
High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Cancer. 2021 Aug 15;127(16):3019-3028. doi: 10.1002/cncr.33571. Epub 2021 Apr 7.
3
Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
Clin Lung Cancer. 2020 May;21(3):e182-e190. doi: 10.1016/j.cllc.2019.11.006. Epub 2019 Nov 21.
4
Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers.
Mol Cancer Ther. 2018 May;17(5):1123-1132. doi: 10.1158/1535-7163.MCT-17-1015. Epub 2018 Mar 2.
5
Identifying a wide range of actionable variants using capture-based ultra-deep targeted sequencing in treatment-naive patients with primary lung adenocarcinoma.
Int J Clin Exp Pathol. 2020 Mar 1;13(3):525-535. eCollection 2020.
6
Comprehensive analysis of mutations in NSCLC patients in a real-world setting.
Ther Adv Med Oncol. 2022 Jul 16;14:17588359221112474. doi: 10.1177/17588359221112474. eCollection 2022.
7
Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases.
Oncotarget. 2018 Apr 17;9(29):20617-20630. doi: 10.18632/oncotarget.25041.
8
Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
Clin Lung Cancer. 2021 Jul;22(4):e519-e527. doi: 10.1016/j.cllc.2020.11.007. Epub 2020 Dec 2.
9
IMPACT: a whole-exome sequencing analysis pipeline for integrating molecular profiles with actionable therapeutics in clinical samples.
J Am Med Inform Assoc. 2016 Jul;23(4):721-30. doi: 10.1093/jamia/ocw022. Epub 2016 Mar 28.
10
Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer.
Front Oncol. 2021 Jun 16;11:665484. doi: 10.3389/fonc.2021.665484. eCollection 2021.
引用本文的文献
1
Multimodal Imaging to Improve Patient Selection and Optimize Treatment Planning and Delivery for Patients Undergoing Reirradiation: A Scoping Review.
Curr Oncol Rep. 2025 Aug 20. doi: 10.1007/s11912-025-01708-9.
2
Genetic Ancestry and Lung Cancer in Latin American Patients: A Crucial Step for Understanding a Diverse Population.
Clin Lung Cancer. 2025 Jul;26(5):e342-e352. doi: 10.1016/j.cllc.2025.03.004. Epub 2025 Mar 13.
3
Sex Difference in Disease-Related Adverse Events Post-Diagnosis of Lung Cancer Brain Metastases in Medicare Individuals ≥ 66 Years of Age.
Cancers (Basel). 2024 Aug 28;16(17):2986. doi: 10.3390/cancers16172986.
4
Clinical Benefit from Docetaxel +/- Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy.
Cancers (Basel). 2024 Feb 26;16(5):935. doi: 10.3390/cancers16050935.
5
Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer.
Cancers (Basel). 2024 Jan 26;16(3):528. doi: 10.3390/cancers16030528.
6
Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer.
Clin Transl Oncol. 2024 Jun;26(6):1384-1394. doi: 10.1007/s12094-023-03362-8. Epub 2024 Jan 6.
本文引用的文献
1
Machine Learning Models for the Identification of Prognostic and Predictive Cancer Biomarkers: A Systematic Review.
Int J Mol Sci. 2023 Apr 24;24(9):7781. doi: 10.3390/ijms24097781.
2
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
Cancer Discov. 2023 Jul 7;13(7):1556-1571. doi: 10.1158/2159-8290.CD-22-1420.
3
Co-Mutation Status Association with Clinical Outcomes in Patients with -Mutant Non-Small Cell Lung Cancer.
Cancers (Basel). 2022 Dec 12;14(24):6127. doi: 10.3390/cancers14246127.
4
Fatty Acid Synthase Mutations Predict Favorable Immune Checkpoint Inhibitor Outcome and Response in Melanoma and Non-Small Cell Lung Cancer Patients.
Cancers (Basel). 2022 Nov 17;14(22):5638. doi: 10.3390/cancers14225638.
5
Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Combination Therapy as First-Line Treatment for Patients with Advanced -Mutated, Non-Small Cell Lung Cancer: A Systematic Review and Bayesian Network Meta-Analysis.
Cancers (Basel). 2022 Oct 6;14(19):4894. doi: 10.3390/cancers14194894.
6
Radiogenomic System for Non-Invasive Identification of Multiple Actionable Mutations and PD-L1 Expression in Non-Small Cell Lung Cancer Based on CT Images.
Cancers (Basel). 2022 Oct 2;14(19):4823. doi: 10.3390/cancers14194823.
7
A Machine Learning-Based Predictive Model of Epidermal Growth Factor Mutations in Lung Adenocarcinomas.
Cancers (Basel). 2022 Sep 25;14(19):4664. doi: 10.3390/cancers14194664.
8
Oncogenic EFNA4 Amplification Promotes Lung Adenocarcinoma Lymph Node Metastasis.
Cancers (Basel). 2022 Aug 30;14(17):4226. doi: 10.3390/cancers14174226.
9
Antiangiogenesis May Not Be a Universal Booster of EGFR Tyrosine Kinase Inhibitors.
J Thorac Oncol. 2022 Sep;17(9):1063-1066. doi: 10.1016/j.jtho.2022.06.012.
10
Mutation Association with Immune Checkpoint Inhibitor Outcome in Melanoma and Non-Small Cell Lung Cancer.
Cancers (Basel). 2022 Jul 19;14(14):3495. doi: 10.3390/cancers14143495.
Zotero 插件